{"id":51284,"date":"2025-12-17T01:52:08","date_gmt":"2025-12-17T00:52:08","guid":{"rendered":"https:\/\/inmuno.es\/index.php\/2025\/12\/17\/targeting-immune-heterogeneity-in-liver-metastases-through-in-vivo-genetic-engineering-giovanna-giacca\/"},"modified":"2025-12-17T01:52:08","modified_gmt":"2025-12-17T00:52:08","slug":"targeting-immune-heterogeneity-in-liver-metastases-through-in-vivo-genetic-engineering-giovanna-giacca","status":"publish","type":"post","link":"https:\/\/inmuno.es\/index.php\/2025\/12\/17\/targeting-immune-heterogeneity-in-liver-metastases-through-in-vivo-genetic-engineering-giovanna-giacca\/","title":{"rendered":"Targeting immune heterogeneity in liver metastases through in vivo genetic engineering. Giovanna Giacca"},"content":{"rendered":"
\n

Semin Immunol<\/b>. 2025 Dec 15;81:102012. doi: 10.1016\/j.smim.2025.102012. Online ahead of print.<\/p>\n

ABSTRACT<\/b><\/p>\n

The liver is both a central metabolic organ and a uniquely tolerogenic immune niche, which makes it a frequent site of liver metastases (LMS) and a challenging environment for immunotherapy. It is increasingly appreciated that resident liver cells- Kupffer cells, Ito cells, liver sinusoidal endothelial cells – as well as infiltrating myeloid and lymphoid populations, collectively establish an immunosuppressive microenvironment that favors metastatic seeding and progression. Advances in our understanding of these cell-cell interactions and the exclusion of effector T cells, have highlighted new therapeutic entry points. In parallel, innovations in gene-delivery platforms, from lentiviral and AAV vectors to lipid nanoparticles, and in engineered immune cells such as CAR-T and CAR-NK cells, are opening avenues to modulate the hepatic tumor niche. Here we review how these insights into liver immunobiology inform the design of next-generation immunotherapies for LMS, emphasizing opportunities and challenges in translating them to the clinic.<\/p>\n

PMID:41401477<\/a> | DOI:10.1016\/j.smim.2025.102012<\/a><\/p>\n<\/div>","protected":false},"excerpt":{"rendered":"

Semin Immunol. 2025 Dec 15;81:102012. doi: 10.1016\/j.smim.2025.102012. Online ahead of print. ABSTRACT The liver is both a central metabolic organ and a uniquely tolerogenic immune niche, which makes it a frequent site of liver metastases (LMS) and a challenging environment for immunotherapy. It is increasingly appreciated that resident liver cells- Kupffer cells, Ito cells, liver … Read more<\/a><\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[42,110],"tags":[],"class_list":["post-51284","post","type-post","status-publish","format-standard","hentry","category-publicaciones","category-seminars-in-immunology"],"_links":{"self":[{"href":"https:\/\/inmuno.es\/index.php\/wp-json\/wp\/v2\/posts\/51284","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/inmuno.es\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/inmuno.es\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/inmuno.es\/index.php\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/inmuno.es\/index.php\/wp-json\/wp\/v2\/comments?post=51284"}],"version-history":[{"count":0,"href":"https:\/\/inmuno.es\/index.php\/wp-json\/wp\/v2\/posts\/51284\/revisions"}],"wp:attachment":[{"href":"https:\/\/inmuno.es\/index.php\/wp-json\/wp\/v2\/media?parent=51284"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/inmuno.es\/index.php\/wp-json\/wp\/v2\/categories?post=51284"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/inmuno.es\/index.php\/wp-json\/wp\/v2\/tags?post=51284"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}